Piclozotan Explained
Piclozotan (SUN-N4057) is a selective 5-HT1A receptor partial agonist, which has neuroprotective effects in animal studies.[1] It has been through early clinical trials in humans for treatment of acute stroke, but results have not yet been announced.[2] [3]
See also
Notes and References
- Kamei K, Maeda N, Nomura K, Shibata M, Katsuragi-Ogino R, Koyama M, Nakajima M, Inoue T, Ohno T, Tatsuoka T . 6 . Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan . Bioorganic & Medicinal Chemistry . 14 . 6 . 1978–92 . March 2006 . 16290165 . 10.1016/j.bmc.2005.10.046 .
- Ferro JM, Dávalos A . Other neuroprotective therapies on trial in acute stroke . Cerebrovascular Diseases . 21 Suppl 2 . 2 . 127–30 . 2006 . 16651823 . 10.1159/000091712 . 39193793 .
- Mondick JT, Oo C, Patel D, Fujitani T, Shimizu K, Barrett JS . Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan . American Journal of Therapeutics . 16 . 2 . 106–15 . 2009 . 19300037 . 10.1097/MJT.0b013e31816b8c85 . 21284395 .